This is a prescription for disaster. While all medications carry potential side effects, certain types have been shown to ...

Adverse side effects of recently approved Alzheimer’s therapy, lecanemab, are ‘manageable', reported a new study published in JAMA Neurology. The findings may inform discussions about the risks of ...

Even after years of warnings, millions of older Americans with dementia are still being prescribed risky brain-altering drugs—often with no clear medical justification. Even after years of clinical ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the approval of the drug on Thursday. Indiana-based pharmaceutical company Eli ...

With over 7 million people over 65 dealing with the degenerative disease — and the number expected to almost double by 2050 — Alzheimer’s is the most common form of dementia. But two new ...

To learn more about the drug’s serious side effects, talk with your doctor or see donepezil’s prescribing information. The side effects of donepezil are generally the same regardless of age. But ...

Researchers have found that 40 Hz auditory stimulation may help clear the brain of amyloid plaques. Read on to ​discover more ...

Despite longstanding guidelines, many dementia patients are still prescribed brain-altering medications that can raise the ...

Years after doctors were warned to be cautious, many Americans with dementia continue to receive medications that can worsen ...

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

Activating two somatostatin receptors enhances amyloid beta breakdown and improves memory in models of Alzheimer’s disease. Scientists at Karolinska Institutet in Sweden and the RIKEN Center for Brain ...

A new drug candidate shows promise by reversing cognitive decline in advanced Alzheimer's disease by restoring brain balance ...